Subsequent therapy after first-line AFATINIB failure can extend survival in countries with optimized cancer care
Document ID: PC-VN-101459
28/06/2021
Author: Boehringer Ingelheim
123,000
Views
100k 340
NHỮNG NỘI DUNG LIÊN QUAN
PC-VN-101459
Production date: June 2021
Production date: June 2021